I-Mab (IMAB) schedules October 24, 2025 Extraordinary General Meeting for shareholders

Rhea-AI Filing Summary

I-Mab has scheduled an Extraordinary General Meeting of Shareholders for October 24, 2025 at 10:00 a.m. local time. The meeting will take place at the offices of Kirkland & Ellis LLP in Washington, D.C.

The company has made materials for the meeting available on its website, though that information is explicitly not part of this report. Attached documents include a proxy statement, formal meeting notice, form of proxy, and a voting card with instructions for ADS holders, all of which are incorporated by reference into existing Form F-3 and Form S-8 registration statements.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-39173

I-MAB

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

Extraordinary General Meeting

I-Mab (the “Company”) will hold an Extraordinary General Meeting of Shareholders (the “Meeting”) on October 24, 2025 beginning at 10:00 a.m. (local time) at the offices of Kirkland & Ellis LLP, the Company’s U.S. legal counsel, located at 1301 Pennsylvania Avenue, N.W., Washington, DC 20004.

Materials made available in connection with the Meeting are available on the Company's website at www.i-mabbiopharma.com. The information contained in, or that can be accessed through, the Company’s website is not a part of this filing.

Incorporation by Reference

The following documents regarding the Meeting, each of which are attached as an exhibit hereto, are incorporated by reference herein. The information and exhibits set forth in this Report on Form 6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684, File No. 333-279842 and File No. 333-290195) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Proxy Statement
99.2	Notice of Extraordinary General Meeting
99.3	Form of Proxy
99.4	Voting Card and Instructions for ADS Holders

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	I-MAB
	By	:	/s/ Joseph Skelton
	Name	:	Joseph Skelton
	Title	:	Chief Financial Officer

Date: September 24, 2025

FAQ

When is I-Mab (IMAB) holding its Extraordinary General Meeting?

I-Mab will hold its Extraordinary General Meeting of Shareholders on October 24, 2025 at 10:00 a.m. local time. The meeting is an additional shareholder gathering outside the regular annual meeting cycle, typically to consider specific corporate matters requiring shareholder approval.

Where will I-Mab’s October 24, 2025 Extraordinary General Meeting take place?

The Extraordinary General Meeting will be held at Kirkland & Ellis LLP, 1301 Pennsylvania Avenue, N.W., Washington, DC 20004. This location is the office of I-Mab’s U.S. legal counsel and serves as the physical venue for shareholders who attend in person.

What materials has I-Mab (IMAB) provided for the Extraordinary General Meeting?

I-Mab has provided a proxy statement, a formal notice of the Extraordinary General Meeting, a form of proxy, and a voting card with instructions for ADS holders. These documents support shareholders in understanding proposals and participating in the meeting.

How can I-Mab (IMAB) shareholders access the Extraordinary General Meeting documents?

Materials for the Extraordinary General Meeting are available on I-Mab’s website at www.i-mabbiopharma.com. While accessible online for convenience, the company notes that website information itself is not considered part of this specific report.

How does this I-Mab 6-K relate to the company’s registration statements?

The report incorporates by reference the attached meeting documents into I-Mab’s Form F-3 and multiple Form S-8 registration statements. This means those proxy and meeting materials are legally treated as part of the referenced registration statements from the furnishing date.

What exhibits are attached to I-Mab’s September 2025 Form 6-K?

The Form 6-K includes four exhibits: a proxy statement, the notice of Extraordinary General Meeting, a form of proxy, and a voting card with instructions for ADS holders. These attachments provide the detailed information and tools needed for shareholder voting.